Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Launched by AGELESSRX · Jul 28, 2025

Keywords

ClinConnect Summary

Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants w...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New or existing AgelessRx patient
• • Adults (aged 18-65)
• • Any sex
• • Any ethnicity
• • BMI ≥ 20 kg/m\^2
• • Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.
• Exclusion Criteria:
• • Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
• • History of bariatric surgery
• • Use of other weight-loss medications currently or within the past 6 months
• • Contraindications to semaglutide
• • Significant psychiatric illness that may affect participation
• • Pregnant or breastfeeding individuals